Becton, Dickinson and Company has struggled over the past decade, with a 10-year CAGR of only 5.1%. Read what keeps me on the ...

Shares of Becton Dickinson & Co. BDX advanced 1.05% to $204.45 Thursday, on what proved to be an all-around positive trading ...

Valued at a market cap of $57.1 billion, Becton, Dickinson and Company (BDX) is a global medical technology company that ...

Becton, Dickinson and Company (BD) has received the US Food and Drug Administration’s (FDA) 510(k) clearance for the Phasix ...

4 analysts have expressed a variety of opinions on Becton Dickinson BDX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their ...

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

The platform comprises Acumen Hypotension Prediction Index software to predict potential low blood pressure events.

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $260.00.

Choice Dekho proudly announces the launch of its live SAP IBP Demand Planning training sessions, conducted by seasoned ...

Shares of Becton Dickinson & Co. BDX rose 1.22% to $202.32 Wednesday, on what proved to be an all-around favorable trading ...